International Cost-Effectiveness Analysis of Durvalumab in Stage III Non-Small Cell Lung Cancer.
Kareff SA, Han S, Haaland B, Jani CJ, Kohli R, Aguiar PN Jr, Huang Y, Soo RA, Rodríguez-Perez Á, García-Foncillas J, Dómine M, de Lima Lopes G.
Kareff SA, et al. Among authors: aguiar pn jr.
JAMA Netw Open. 2024 May 1;7(5):e2413938. doi: 10.1001/jamanetworkopen.2024.13938.
JAMA Netw Open. 2024.
PMID: 38814640